284 related articles for article (PubMed ID: 24926510)
1. Tapentadol. Acute or chronic pain: no therapeutic advance.
Prescrire Int; 2014 May; 23(149):121-4. PubMed ID: 24926510
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
3. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
6. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol for pain: a treatment evaluation.
Hartrick CT; Rodríguez Hernandez JR
Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
[TBL] [Abstract][Full Text] [Related]
9. Tapentadol extended release for chronic pain patients.
Taylor R; Pergolizzi JV; Raffa RB
Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
[TBL] [Abstract][Full Text] [Related]
10. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.
Vorsanger GJ; Klopfer AM; Xiang J; Benson CJ; Moskovitz BL; Rosenthal NR
J Opioid Manag; 2013; 9(4):281-90. PubMed ID: 24353022
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
[TBL] [Abstract][Full Text] [Related]
12. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
13. Unique pharmacology of tapentadol for treating acute and chronic pain.
Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
[TBL] [Abstract][Full Text] [Related]
18. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
[TBL] [Abstract][Full Text] [Related]
19. [Sustained-release Opioids: Morphine, Oxycodone and Tapentadol].
Takahashi Y; Iseki M
Masui; 2015 Nov; 64(11):1133-40. PubMed ID: 26689063
[TBL] [Abstract][Full Text] [Related]
20. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
